Hbk Investments L P Blueprint Medicines Corp Transaction History

Hbk Investments L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $1.9 Million - $3.38 Million	-39,051 Reduced 73.75%	13,900 $1.11 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $1.22 Million - $1.62 Million	-20,634 Reduced 28.04%	52,951 $4.13 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $3.68 Million - $6.11 Million	60,429 Added 459.33%	73,585 $4.67 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $180,342 - $253,359	2,461 Added 23.01%	13,156 $1.21 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $376,893 - $529,125	-5,991 Reduced 35.9%	10,695 $807,000
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $706,985 - $1.16 Million	16,686	16,686 $1.16 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Hbk Investments L P, based on Form 13F filings with the SEC.

Stay updated on Hbk Investments L P with notifications on news.